ArticleNeoplasia (New York, N.Y.)2012

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Stefanie Derer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.